PMID- 25667129
OWN - NLM
STAT- MEDLINE
DCOM- 20151117
LR  - 20181113
IS  - 1558-822X (Electronic)
IS  - 1558-8211 (Linking)
VI  - 10
IP  - 1
DP  - 2015 Mar
TI  - Alternative donor transplantation--"mixing and matching": the role of combined 
      cord blood and haplo-identical donor transplantation (haplo-cord SCT) as a 
      treatment strategy for patients lacking standard donors?
PG  - 1-7
LID - 10.1007/s11899-014-0245-y [doi]
AB  - In the past decade, haplo-cord stem cell transplantation (SCT) using 
      myeloablative or reduced intensive conditioning regimens has been shown to result 
      in reliable and fast engraftment of neutrophils and platelets comparable to 
      HLA-matched donors and much faster than after cord stem cell transplant. 
      Haplo-cord SCT also has a low incidence of early non-relapse mortality, low 
      incidences of acute and chronic graft-vs-host disease (GVHD), and excellent 
      graft-vs-leukemia (GVL) effects. Favorable long-term outcomes for high-risk 
      patients with hematologic malignancies have been reported, including older 
      patients. Haplo-cord SCT will likely overcome the limitations of cell dose during 
      cord stem cell selection and might significantly expand the use of cord stem cell 
      transplant in the adult population. The comparable survival outcomes of matched 
      related donor (MRD), matched unrelated donor (MUD), and haplo-cord stem cell 
      transplant strongly argue that haplo-cord SCT should be considered as effective 
      alternative stem cell transplant for high-risk patients lacking standard donors. 
      Further improvement in supportive care and incorporation of a better 
      understanding of the human fetal immune development into the haplo-cord SCT are 
      required to further improve this strategy.
FAU - Liu, Hongtao
AU  - Liu H
AD  - Section of Hematology/Oncology, Department of Medicine, University of Chicago, 
      Chicago, IL, USA, hliu2@medicine.bsd.uchicago.edu.
FAU - van Besien, Koen
AU  - van Besien K
LA  - eng
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Hematol Malig Rep
JT  - Current hematologic malignancy reports
JID - 101262565
SB  - IM
MH  - Chimerism
MH  - Cord Blood Stem Cell Transplantation/*methods
MH  - Graft Survival
MH  - Graft vs Host Disease/prevention & control
MH  - Hematologic Neoplasms/*therapy
MH  - Humans
MH  - Survival Rate
MH  - Transplantation Conditioning/methods
EDAT- 2015/02/11 06:00
MHDA- 2015/11/18 06:00
CRDT- 2015/02/11 06:00
PHST- 2015/02/11 06:00 [entrez]
PHST- 2015/02/11 06:00 [pubmed]
PHST- 2015/11/18 06:00 [medline]
AID - 10.1007/s11899-014-0245-y [doi]
PST - ppublish
SO  - Curr Hematol Malig Rep. 2015 Mar;10(1):1-7. doi: 10.1007/s11899-014-0245-y.